WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
As a critical component of WuXi XDC's global strategy, the Singapore site has demonstrated exceptional progress, adhering to the perfect execution and the 'WuXi Speed' to provide customers with agile and flexible end-to-end CRDMO services. According to current capacity plan, the site is anticipated to create more than 500 job opportunities and over 100 people have joined our company so far.
Dr. Jimmy Li, CEO of WuXi XDC, stated, " The rapid mechanical completion of our Singapore site marks a critical pillar in our 'Global Dual-Sourcing' strategy. This global site will form a worldwide network alongside our Wuxi, Changzhou, and Shanghai sites, delivering end-to-end CRDMO services to global customers. This accomplishment showcases the full support of the partners for the construction of Singapore site, our deep understanding of global market demands, our ability to respond swiftly and the robust execution capabilities of our team. Looking ahead, we remain committed to advancing our one-stop model and global supply network, collaborating with global partners to promote the diversified and sustainable development of bioconjugates.'
The Singapore site serves as a world-class, one-stop bioconjugates manufacturing center, integrating antibody intermediates, drug substance (DS), and drug products (DP). It strictly adheres to international certification standards and utilizes an advanced modular factory design. Key features include state-of-the-art antibody intermediates production lines, bioconjugate DS and DP production lines, MSAT lab, quality control, intelligent warehousing, and other utility support areas. Equipped with cutting-edge isolator filling lines, fully automated material transfer systems, and digital production management systems, the Singapore site supports multi-level demands ranging from small-scale clinical supplies to large-scale commercial manufacturing, including up to 2,000 liters per batch of mAb/DS, and 8 million vials of DP per year. These capabilities ensure the efficient advancement of projects across various stages while maintaining adherence to the highest quality standards.
The Singapore site will be operated under the highest international quality assurance standards, fully complying with Good Manufacturing Practice (GMP) regulations established by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China's National Medical Products Administration (NMPA). This ensures comprehensive compliance throughout the production process, from antibody intermediates and DS to DP, enabling seamless product release globally. Additionally, the site incorporates environmentally friendly practices, utilizing certified eco-friendly products and implementing strict recycling and waste disposal systems to promote sustainability and enhance the company's ESG management level.
About WuXi XDC
WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from clinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com
WuXi XDC Contacts
Investor: [email protected]
Media: [email protected]
BD: [email protected]
View original content: https://www.prnewswire.com/news-releases/wuxi-xdc-announces-the-mechanical-completion-of-its-singapore-site-accelerating-the-global-expansion-of-bioconjugates-manufacturing-302495535.html
SOURCE WuXi XDC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
ICICI Bank Ltd (IBN) Q1 2026 Earnings Call Highlights: Strong Profit Growth Amid Asset Quality ...
Release Date: July 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points ICICI Bank Ltd (NYSE:IBN) reported a 15.5% year-on-year increase in profit after tax, reaching ?127.68 billion for the quarter. The bank's core operating profit increased by 13.6% year-on-year to ?175.05 billion. Total deposits grew by 12.8% year-on-year, with average deposits increasing by 11.2% year-on-year and 3.1% sequentially. The business banking portfolio showed strong growth, increasing by 29.7% year-on-year and 3.7% sequentially. ICICI Bank Ltd (NYSE:IBN) maintained a strong capital position with a CET1 ratio of 16.31% and a total capital adequacy ratio of 16.97%. Negative Points The rural loan portfolio declined by 0.4% year-on-year and 1.5% sequentially. The retail loan portfolio growth was modest, increasing by only 6.9% year-on-year and 0.5% sequentially. The net interest margin decreased to 4.34% from 4.41% in the previous quarter. There were net additions of ?30.34 billion to gross NPAs, indicating ongoing challenges in asset quality. The overseas loan portfolio remained small, constituting only 2.4% of the overall loan book. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with IBN. Q: Can you provide a like-to-like comparison of margins for the fourth quarter, considering the change in method and the impact of the tax refund? A: The reported margin for Q4 would have been a few basis points lower, and the range you mentioned is probably correct. However, the same spike will not occur in the current year, and we expect a more even spread of the reported margin throughout the year. (Unidentified_3) Q: With the current credit cost, do you expect further normalization, or is this the clean credit cost we should expect going forward? A: The underlying level is currently around 50 basis points, and we don't foresee any major movement. The current credit cost is reflective of the underlying conditions. (Unidentified_3) Q: Regarding the business banking segment, what factors contributed to the strong performance, and how do you see the mix of credit growth evolving over the next few years? A: The success in business banking is due to a combination of distribution, process, technology, and digital capabilities. We expect business banking fees to grow faster than the overall loan book, gradually increasing its proportion. (Unidentified_3) Q: How do you see the behavior of CASA deposits changing with rate cuts, and do you expect market share to stabilize or grow? A: We don't see a significant change in the competitive scenario. We will continue to focus on increasing customer acquisition and becoming the primary banker, which should help us maintain or grow our market share. (Unidentified_3) Q: How are you approaching unsecured retail growth, given the systemic softness in credit demand? A: We are comfortable with the quality of origination in personal loans and credit cards over the last 12-15 months. We expect to see better growth and customer acquisition in these segments going forward. (Unidentified_3) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
3 Asian Stocks Estimated To Be Trading Up To 39.1% Below Intrinsic Value
As Asian markets navigate a landscape marked by political uncertainties and trade tensions, investors are increasingly looking for opportunities that promise value amidst volatility. Identifying stocks trading below their intrinsic value can be a prudent strategy in such an environment, offering potential upside as market conditions stabilize. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) PropNex (SGX:OYY) SGD1.34 SGD2.67 49.7% Medy-Tox (KOSDAQ:A086900) ₩163000.00 ₩322233.66 49.4% Mandom (TSE:4917) ¥1427.00 ¥2828.12 49.5% Lucky Harvest (SZSE:002965) CN¥35.75 CN¥70.35 49.2% Japan Eyewear Holdings (TSE:5889) ¥2151.00 ¥4222.53 49.1% HL Holdings (KOSE:A060980) ₩41300.00 ₩81736.71 49.5% Cosmax (KOSE:A192820) ₩243000.00 ₩483155.97 49.7% Astroscale Holdings (TSE:186A) ¥673.00 ¥1324.01 49.2% ALUX (KOSDAQ:A475580) ₩11490.00 ₩22617.71 49.2% Accton Technology (TWSE:2345) NT$798.00 NT$1590.11 49.8% Click here to see the full list of 255 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. GC Biopharma Overview: GC Biopharma Corp. is a biopharmaceutical company that develops and sells pharmaceutical drugs both in South Korea and internationally, with a market cap of approximately ₩1.75 trillion. Operations: The company's revenue primarily comes from the manufacturing and sales of pharmaceuticals, totaling ₩1.65 trillion, complemented by ₩200.20 million from diagnosis and analysis of samples, etc. Estimated Discount To Fair Value: 38.4% GC Biopharma is trading at 38.4% below its estimated fair value, highlighting its potential as an undervalued stock based on cash flows. Despite a low forecasted return on equity of 4.3%, the company has become profitable this year with significant earnings growth expected to outpace the KR market. Recent product approvals and trials, such as BARYCELA's entry into Vietnam and Hunterase's promising Phase 3 results, bolster revenue prospects amidst robust sector demand. Upon reviewing our latest growth report, GC Biopharma's projected financial performance appears quite optimistic. Navigate through the intricacies of GC Biopharma with our comprehensive financial health report here. Beijing Kawin Technology Share-Holding Overview: Beijing Kawin Technology Share-Holding Co., Ltd. is a biopharmaceutical company that offers treatment solutions for viral and immune diseases in China, with a market cap of CN¥5.38 billion. Operations: The company's revenue primarily comes from its Medicine Manufacturing segment, which generated CN¥1.25 billion. Estimated Discount To Fair Value: 39.1% Beijing Kawin Technology Share-Holding is trading 39.1% below its estimated fair value of CN¥52.74, presenting it as an undervalued stock based on cash flows. Despite a forecasted earnings growth of 20.67% per year, which is slower than the market average, revenue growth at 20% annually outpaces the market's 12.5%. Recent Q1 results show increased sales and net income compared to last year, although dividends remain minimally covered by free cash flows. The analysis detailed in our Beijing Kawin Technology Share-Holding growth report hints at robust future financial performance. Click to explore a detailed breakdown of our findings in Beijing Kawin Technology Share-Holding's balance sheet health report. Rayhoo Motor DiesLtd Overview: Rayhoo Motor Dies Co., Ltd. designs, develops, manufactures, and sells stamping dies and auto welding lines both in China and internationally, with a market cap of CN¥8.59 billion. Operations: Rayhoo Motor Dies Ltd generates its revenue from the design, development, manufacturing, and sale of stamping dies and auto welding lines across domestic and international markets. Estimated Discount To Fair Value: 32.3% Rayhoo Motor Dies Ltd. trades at 32.3% below its estimated fair value of CNY 60.66, highlighting its undervaluation based on cash flows. Despite earnings growth forecasts of 21.8% annually, slightly below the market average, revenue is expected to grow robustly at 25.8%, surpassing the market's rate. Recent Q1 results show significant sales and net income increases year-on-year, though dividends are not well covered by free cash flows. Our comprehensive growth report raises the possibility that Rayhoo Motor DiesLtd is poised for substantial financial growth. Unlock comprehensive insights into our analysis of Rayhoo Motor DiesLtd stock in this financial health report. Where To Now? Embark on your investment journey to our 255 Undervalued Asian Stocks Based On Cash Flows selection here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Ready To Venture Into Other Investment Styles? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A006280 SHSE:688687 and SZSE:002997. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
ICICI Bank Ltd (IBN) Q1 2026 Earnings Call Highlights: Strong Profit Growth Amid Asset Quality ...
Release Date: July 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points ICICI Bank Ltd (NYSE:IBN) reported a 15.5% year-on-year increase in profit after tax, reaching ?127.68 billion for the quarter. The bank's core operating profit increased by 13.6% year-on-year to ?175.05 billion. Total deposits grew by 12.8% year-on-year, with average deposits increasing by 11.2% year-on-year and 3.1% sequentially. The business banking portfolio showed strong growth, increasing by 29.7% year-on-year and 3.7% sequentially. ICICI Bank Ltd (NYSE:IBN) maintained a strong capital position with a CET1 ratio of 16.31% and a total capital adequacy ratio of 16.97%. Negative Points The rural loan portfolio declined by 0.4% year-on-year and 1.5% sequentially. The retail loan portfolio growth was modest, increasing by only 6.9% year-on-year and 0.5% sequentially. The net interest margin decreased to 4.34% from 4.41% in the previous quarter. There were net additions of ?30.34 billion to gross NPAs, indicating ongoing challenges in asset quality. The overseas loan portfolio remained small, constituting only 2.4% of the overall loan book. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with IBN. Q: Can you provide a like-to-like comparison of margins for the fourth quarter, considering the change in method and the impact of the tax refund? A: The reported margin for Q4 would have been a few basis points lower, and the range you mentioned is probably correct. However, the same spike will not occur in the current year, and we expect a more even spread of the reported margin throughout the year. (Unidentified_3) Q: With the current credit cost, do you expect further normalization, or is this the clean credit cost we should expect going forward? A: The underlying level is currently around 50 basis points, and we don't foresee any major movement. The current credit cost is reflective of the underlying conditions. (Unidentified_3) Q: Regarding the business banking segment, what factors contributed to the strong performance, and how do you see the mix of credit growth evolving over the next few years? A: The success in business banking is due to a combination of distribution, process, technology, and digital capabilities. We expect business banking fees to grow faster than the overall loan book, gradually increasing its proportion. (Unidentified_3) Q: How do you see the behavior of CASA deposits changing with rate cuts, and do you expect market share to stabilize or grow? A: We don't see a significant change in the competitive scenario. We will continue to focus on increasing customer acquisition and becoming the primary banker, which should help us maintain or grow our market share. (Unidentified_3) Q: How are you approaching unsecured retail growth, given the systemic softness in credit demand? A: We are comfortable with the quality of origination in personal loans and credit cards over the last 12-15 months. We expect to see better growth and customer acquisition in these segments going forward. (Unidentified_3) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
